Forest looks to evergreen Namenda through Adamas deal for fixed-dose donepezil combo
This article was originally published in Scrip
Executive Summary
Forest Laboratories has paid $65 million up front to license Adamas Pharmaceuticals' proprietary fixed-dose combination (FDC) of memantine and donepezil in the US, giving Forest an opportunity to extend the life of its Namenda (memantine hydrochloride) franchise in moderate-to-severe dementia associated with Alzheimer's disease.